^
    18d
    Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma. (PubMed, Signal Transduct Target Ther)
    Grade 3 or higher treatment-related adverse events were observed in 63 (76.8%) cases, with neutropenia (22.0%), hyperglycemia (19.5%), and diarrhea (13.4%) being common. TQ-B3525 showed favorable efficacy and safety for R/R FL patients after ≥2 lines prior therapies.
    P2 data • Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    TQ-B3525
    5ms
    A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P1/2, N=23, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=80 --> 23 | Trial completion date: Feb 2024 --> Nov 2023 | Recruiting --> Terminated | Trial primary completion date: Feb 2023 --> Nov 2023; The sponsor terminated the study due to the R&D strategy change.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    TQ-B3525
    3years
    A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors (clinicaltrials.gov)
    P2, N=90, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Clinical • New P2 trial
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1)
    |
    TQ-B3525
    over3years
    TQBSP: TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss (clinicaltrials.gov)
    P1/2, N=29, Active, not recruiting, Peking University People's Hospital
    Clinical • New P1/2 trial
    |
    PTEN (Phosphatase and tensin homolog)
    |
    PTEN loss
    |
    TQ-B3525
    4years
    A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=42, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Clinical • New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    HR positive • HER-2 negative • PIK3CA mutation
    |
    fulvestrant • TQ-B3525